Call for Abstract

12th International Conference on Vascular Dementia, will be organized around the theme “New and Emerging Target Therapies in Vascular Dementia”

Vascular Dementia Congress 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Vascular Dementia Congress 2019

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Dementia is a chronic or persistent disorder of the mental ability process caused by brain diseases or injuries marked due to personality changes, memory disorders and impaired reasoning. Dementia is not a specific disease. It's a group of symptoms related with a decline in memory or other thinking ability skills enough to reduce a person's ability activities. Various kinds of dementia are associated with particular types of brain cell damage in particular regions of the brain

 

  • Track 1-1Memory
  • Track 1-2Communication and language
  • Track 1-3Ability to focus and pay attention
  • Track 1-4Reasoning and judgment
  • Track 1-5Visual perception

Vascular dementia, which occurs after a stroke, is the second most common dementia type. But there are many other conditions that can cause symptoms of dementia, including some that are reversible, such as thyroid problems and vitamin deficiencies. In vascular dementia, changes in thinking skills sometimes occur suddenly following strokes that block major brain blood vessels. Thinking problems also may begin as mild changes that worsen gradually as a result of multiple minor strokes or other conditions that affect smaller blood vessels, leading to cumulative damage. Vascular dementia symptoms can vary widely, depending on the severity of the blood vessel damage and the part of the brain affected. Memory loss may or may not be a significant symptom depending on the specific brain areas where blood flow is reduced. Symptoms may be most obvious when they happen soon after a major stroke.

 

  • Track 2-1Confusion
  • Track 2-2Disorientation
  • Track 2-3Trouble speaking or understanding speech
  • Track 2-4Vision loss

In Alzheimer's disease, high levels of certain proteins inside and outside brain cells make it hard for brain cells to stay healthy and to communicate with each other. The brain region called the hippocampus is the center of learning and memory in the brain, and the brain cells in this region are often the first to be damaged. That's why memory loss is often one of the earliest symptoms of Alzheimer's. While most changes in the brain that cause dementia are permanent and worsen over time, thinking and memory problems caused by various conditions

 

  • Track 3-1Depression
  • Track 3-2Medication side effects
  • Track 3-3Excess use of alcohol
  • Track 3-4Thyroid problems
  • Track 3-5Vitamin deficiencies

Dementia in “stages,” refers how far a person’s dementia has been progressed. It defines a person’s disease stage helping physicians to determine the best treatment approach and aid communication between health providers and caregivers. Sometimes the stage is simply referred to as “early stage”, “middle stage” or “late-stage” dementia, but often a more exact stage is assigned, based on a person’s symptoms.

  • Global Deterioration Scale for Assessment of Primary Degenerative Dementia (GDS)
    • Cognitive Decline
    • Very Mild Cognitive Decline
    • Mild Cognitive Decline
    • Moderate Cognitive Decline
    • Moderately Severe Cognitive Decline
    • Severe Cognitive Decline (Middle Dementia)
    • Very Severe Cognitive Decline (Late Dementia)
  • Functional Assessment Staging (FAST)
  • Clinical Dementia Rating (CDR) – No dementia, Moderate, Mild , Severe.

 

  • Track 4-1Global Deterioration Scale for Assessment of Primary Degenerative Dementia (GDS)
  • Track 4-2Functional Assessment Staging (FAST)
  • Track 4-3Clinical Dementia Rating (CDR) – No dementia, Moderate, Mild , Severe

People with Lewy body dementia have a progressive decline in their memory and ability to think; similar to Alzheimer’s disease. However, the cognitive ability or alertness of a person with Lewy body dementia is more likely to fluctuate from one moment to the next, which is not like Alzheimer’s disease. They also often have visual hallucinations (seeing things that aren’t there) and delusions (believing something that is not true). On the surface, people with Lewy body dementia often have problems with movement that resemble Parkinson’s disease. This is because the same structures of the brain are affected in Lewy body dementia and Parkinson’s disease.

 

  • Track 5-1Causes of Lewy Body Dementia
  • Track 5-2Causes of Lewy Body Dementia
  • Track 5-3Symptoms of Lewy Body Dementia
  • Track 5-4Diagnosing Lewy Body
  • Track 5-5Diagnosing dementia (general)
  • Track 5-6Treating dementia

Neurodegenerative disease primarily affects the neurons in the human brain. Neurons are the building blocks of the nervous system which includes the brain and spinal cord. Neurons normally don’t reproduce or replace themselves, so when they become damaged or die they cannot be replaced by the body. Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration and / or death of nerve cells. This causes problems with movement (called ataxias), or mental functioning (called dementias). Dementias are responsible for the greatest burden of neurodegenerative diseases, with Alzheimer’s representing approximately 60-70% of dementia cases.

 

  • Track 6-1Alzheimer’s disease (AD) and other dementias
  • Track 6-2Parkinson’s disease (PD) and PD-related disorders
  • Track 6-3Prion disease
  • Track 6-4Motor neurone diseases (MND)
  • Track 6-5Huntington’s disease (HD)
  • Track 6-6Spinocerebellar ataxia (SCA)
  • Track 6-7Spinal muscular atrophy (SMA)

The brain is the control center of the body. It controls thoughts, memory, speech, and movement. It regulates the function of many organs. When the brain is healthy, it works quickly and automatically. However, when problems occur, the results can be devastating. Inflammation in the brain can lead to problems such as vision loss, weakness and paralysis. Loss of brain cells, which happens if you suffer a stroke, can affect your ability to think clearly. Brain tumors can also press on nerves and affect brain function. Some brain diseases are genetic. And we do not know what causes some brain diseases, such as Alzheimer's disease.

 

  • Track 7-1Hematomas
  • Track 7-2Seizures
  • Track 7-3Huntington’s disease
  • Track 7-4ALS (amyotrophic lateral sclerosis), or Lou Gehrig’s disease
  • Track 7-5Parkinson’s disease
  • Track 7-6Depression
  • Track 7-7Bipolar disorder
  • Track 7-8Post-traumatic stress disorder (PTSD)
  • Track 7-9Schizophrenia

Parkinson's disease (PD) is an age-related degenerative disorder of certain brain cells. It mainly affects movements of the body, but other problems, including dementia, may occur. It is not considered a hereditary disease, although a genetic link has been identified in a small number of families. Depression, anxiety, personality and behavior changes, sleep disturbances, and sexual problems are commonly associated with Parkinson's disease. In many cases, Parkinson's disease does not affect a person's ability to think, reason, learn, or remember (cognitive processes).

 

  • Track 8-1Depression
  • Track 8-2Cardiovascular disease
  • Track 8-3Anxiety
  • Track 8-4Psychosis

Neuropharmacology is the scientific study of the effects of drugs on the nervous system. Its primary focus is the actions of medications for psychiatric and neurologic disorders as well as those of drugs of abuse. Drugs that act on the nervous system, including antidepressant, antianxiety, anticonvulsant, and antipsychotic agents, are among the most widely prescribed medications.

 

  • Track 9-1Pharmacogenomics
  • Track 9-2Pharmacoepidemiology
  • Track 9-3Toxicology
  • Track 9-4Posology
  • Track 9-5Pharmacognosy
  • Track 9-6Behavioral Pharmacology

Neuro-oncology is the study of brain and spinal cord neoplasms, many of which are very dangerous and life-threatening (astrocytoma, glioma, glioblastoma multiforme, ependymoma, pontine glioma, and brain stem tumors are among the many examples of these). Among the malignant brain cancers, gliomas of the brainstem and pons, glioblastoma multiforme, and high-grade (highly anaplastic) astrocytoma are among the worst.

The CNS consists of the brain and spinal cord. The brain is protected by the skull (the cranial cavity) and the spinal cord travels from the back of the brain, down the center of the spine, stopping in the lumbar region of the lower back. The brain and spinal cord are both housed within a protective triple-layered membrane called the meninges.

 

  • Track 10-1Brain Stem Tumors
  • Track 10-2Spine Diseases
  • Track 10-3Glioblastoma
  • Track 10-4Meningioma
  • Track 10-5Malignant Brain Cancers and Brain Metastasis
  • Track 10-6Pediatric Neuro Oncology
  • Track 10-7Astrocytoma
  • Track 10-8Neurotoxicity

Vascular cognitive impairment is a decline in thinking abilities caused by disease that damages the brain’s blood vessels. Vascular disease may cause cognitive impairment on its own, and can also contribute to impairments in thinking and behaviour in a person with another brain disease such as Alzheimer’s. 

  • Track 11-1Small vessel disease
  • Track 11-2Ischaemic stroke
  • Track 11-3Haemorrhagic stroke
  • Track 11-4Stroke and vascular cognitive impairment

Treatment of dementia depends on its cause. In the case of most progressive dementias, including Alzheimer's disease, there is no cure and no treatment that slows or stops its progression. But there are drug treatments that may temporarily improve symptoms. The same medications used to treat Alzheimer's are among the drugs sometimes prescribed to help with symptoms of other types of dementias. Non-drug therapies can also alleviate some symptoms of dementia.

 

  • Track 12-1• Psychopharmacological treatment
  • Track 12-2Advanced drugs for dementia
  • Track 12-3Cognitive behavioral therapy
  • Track 12-4Family therapy in nursing

People with Dementia and vascular dementia have different mental element shortfalls that incorporate every memory hindrance, that influences the adaptability to discover new data or review data already learned, and one or extra of the ensuing side effects aphasia, apraxia, agnosia, or official brokenness to such an extent that the mental element shortages adversely affect social or action working with a major decrease in past abilities. Furthermore, people with dementia commonly experience the ill effects of comorbid conditions that extra confuse mind and block best results. Along these lines, creating caregiving techniques individuals with vascular dementia is pressing, given this expanding commonness and consequently the related weight that dementia places not just on the people, however on the parental figures, relations, and thusly the assets of the human services framework. Traditional perspectives bearing on geriatric nursing ordinarily paint a picture of the care as being moderate paced certain and less requesting than intense care. Be that as it may, care of the matured, and especially those with vascular dementia, is normally confounded, unusual, and flimsy.

 

  • Track 13-1Dementia nursing care plan
  • Track 13-2Music therapy in dementia
  • Track 13-3Physiotherapy for dementia
  • Track 13-4Clinical features of dementia
  • Track 13-5Therapeutic interventions in dementia

Therapeutic targets are bio molecules maybe a nucleic acid or a protein whose biological activity can be modified by a drug candidate. In some cases of Dementia, it is reported that proteins are the cause for the disease. For example the accumulation of amyloid protein in the regions of Brain acts as a major factor for the disorder, hence it can be a therapeutic target . Therapeutic targets play an important role in identifying the potential drug candidates . Hence the conference provides the discussion sessions to reveal the targets for drug design process.

 

  • Track 14-1Beta-amyloid Precursor Protein
  • Track 14-2Beta-amyloid Precursor Protein
  • Track 14-3Action of Protein tau
  • Track 14-4Role of Acetylcholinesterase and Inhibition
  • Track 14-5N-methyl-d-aspartate (NMDA) receptor as target
  • Track 14-6Processing of Prion Protein

Rigorous clinical trials on Dementia drugs are continuing in USA and UK under the guidance of Alzheimer's society and it is reported that there is very less participation of people. The most of drugs are in second and third phases. Most of clinical trials are done in specific areas are amyloid beta plaques, the immune system, tau tangles. New medications for Dementia being developed in 2014/2015, 31% were named symptoms modifying. There are many developments are going on in Drug discovery of Dementia as old treatments are unable to stop the progression of Dementia. Most associations share their exploration on new medications for Dementia in Dementia conferences to get higher esteem to their items. This gets to be distinctly gainful to different geriatric doctors to redesign themselves with such medications and progressing possibilities by going to Dementia conferences. Such Dementia meetings will help researchers to know target areas for Drug development in Dementia and work towards it and also Dementia conferences exhibit clinical trial medications and offers positivity to discover new approaches in curing Dementia

 

  • Track 15-1Development of Re-purposed Drugs
  • Track 15-2Beta-amyloid Polymerization and Inflammation Inhibitor
  • Track 15-3Prevention Trials
  • Track 15-4Anticonvulsant Drugs for Treatment
  • Track 15-5Vaccine Development against Beta-Amyloid
  • Track 15-6Animal Models for Toxicology Studies